Detalhe da pesquisa
1.
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
Br J Cancer
; 126(9): 1264-1270, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34992255
2.
Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
BMC Cancer
; 20(1): 74, 2020 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32000724
3.
Hepatitis E Virus Infection in Patients with Chronic Inflammatory Bowel Disease Treated with Immunosuppressive Therapy.
Pathogens
; 12(2)2023 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36839604
4.
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.
Cancer Med
; 12(5): 5341-5351, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394147
5.
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
Dig Liver Dis
; 54(3): 324-330, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35027324
6.
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Hepatol Int
; 15(1): 93-104, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33420951
7.
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.
Cancers (Basel)
; 12(6)2020 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32486421